Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stage Set For India To Frame Compulsory Licensing Provisions As Contrasting Groups Make Their Case

This article was originally published in The Pink Sheet Daily

Executive Summary

The Department of Industrial Policy and Promotion is analyzing and interpreting comments on a contentious subject that has kept Indian and multinational drug firms bitterly divided for more than five years, while forcing the government into a dilemma over an acceptable policy.

You may also be interested in...



PhRMA Meets With Indian Officials To Discuss Compulsory Licensing

Executives of the Pharmaceutical Research and Manufacturers of America were in India the last two weeks of October for meetings with member companies. One issue had grabbed their attention: India’s move toward compulsory licensing.

PhRMA Meets With Indian Officials To Discuss Compulsory Licensing

Executives of the Pharmaceutical Research and Manufacturers of America were in India the last two weeks of October for meetings with member companies. One issue had grabbed their attention: India’s move toward compulsory licensing.

Indian Firms Must Be In Indian Hands, Says Government Paper; Highlights Threats to Compulsory Licensing And Drug Pricing

MUMBAI - Ambitions of leading multinational companies for a long-term positioning in India through acquisition of generic companies may face rigid policy restrictions from a government concerned about monopoly-dictated pricing for needed drugs

Related Content

Topics

UsernamePublicRestriction

Register

PS071394

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel